A Phase 1 interventional study of ABBV-1451 and ABBV-1451 in Healthy Volunteer, sponsored by AbbVie. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Japanese participants:
-- Participant must be first or second-generation Japanese of full Japanese parentage, residing outside of Japan. First generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent. Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent. Participants must be in general good health.
For Han Chinese participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo.
Drug: ABBV-1451 · Other: Placebo
Participants will receive either single ascending doses of ABBV-1451 until they reach Dose B or placebo.
Drug: ABBV-1451 · Other: Placebo
Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo.
Drug: ABBV-1451 · Other: Placebo
Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo.
Drug: ABBV-1451 · Other: Placebo
Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo.
Drug: ABBV-1451 · Other: Placebo
Participants will receive either single ascending doses of ABBV-1451 until they reach Dose TBD or placebo.
Drug: ABBV-1451 · Other: Placebo
Japanese participants will receive a single dose of ABBV-1451 Dose C or placebo.
Drug: ABBV-1451 · Other: Placebo
Han Chinese participants will receive a single dose of ABBV-1451 Dose C or placebo.
Drug: ABBV-1451 · Other: Placebo
Injection
Infusion
Injection
Infusion
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Time frame: Up to Approximately Day 211
Maximum Observed Plasma Concentration (Cmax) of ABBV-1451
Cmax of ABBV-1451.
Time frame: Up to Approximately Day 211
Time to Cmax (Tmax) of ABBV-1451
Tmax of ABBV-1451.
Time frame: Up to Approximately Day 211
Terminal Phase Elimination Rate Constant (β) of ABBV-1451
β of ABBV-1451.
Time frame: Up to Approximately Day 211
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1451
t1/2 of ABBV-1451.
Time frame: Up to Approximately Day 211
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-1451
AUCt of ABBV-1451.
Time frame: Up to Approximately Day 211
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-1451
AUCinf of ABBV-1451.
Time frame: Up to Approximately Day 211
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.